Press release

Top 20 Pharmaceutical Company Selects Veeva Vault CDMS for Enterprise-wide Deployment

Sponsored by Businesswire

(NYSE:VEEV) today announced that a top 20 pharmaceutical
company has selected Veeva
Vault Clinical Data Management System (CDMS)
as their global
standard for EDC, coding, data cleaning, and reporting.

“This is a landmark announcement for the clinical data management
market,” said Henry Levy, general manager, Veeva Vault CDMS. “Veeva
Vault CDMS was selected because the company wanted a modern cloud
solution on a world-class platform from a partner they could trust.”

Vault CDMS provides a suite of clinical data management applications
that combines coding, EDC, data cleaning, and reporting all on a single
cloud platform. Companies can now manage study build through execution
in an integrated way. With a complete and concurrent view of their data,
clinical development teams can make better decisions faster.

As part of Vault CDMS, Veeva
Vault EDC
provides a fast and intuitive interface for capturing
clinical trial data. Designed for flexibility, Vault EDC allows
customers to run complex multi-arm adaptive trials and make mid-study
amendments without downtime or migrations.

“Our goal is to become the market leader in the clinical data management
market over time through innovation and product excellence,” added Levy.
“We are honored to partner with this important customer and look forward
to delivering customer success for many years.”

Additional Information

For more on Veeva Vault CDMS, visit:

Connect with Veeva on LinkedIn:

Follow @veevasystems on Twitter:

Like Veeva on Facebook:

About Veeva Systems

Veeva Systems Inc. is the leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva serves more than 700 customers, ranging from the
world’s largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices throughout
North America, Europe, Asia, and Latin America. For more information,

Forward-looking Statements

This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-K for the period ended January 31, 2019. This is available on the
company’s website at
under the Investors section and on the SEC’s website at
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to